CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery
- PMID: 30348713
- PMCID: PMC6365743
- DOI: 10.21873/invivo.11411
CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery
Abstract
Background/aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of digestive cancer. Recurrence within one year after surgery is inevitable in most PDAC patients. Recently, cluster of differentiation 44 (CD44) has been shown to be associated with tumor initiation, metastasis and prognosis. This study aimed to explore the correlation of CD44 expression with clinicopathological factors and the role of CD44 in predicting early recurrence (ER) in PDAC patients after radical surgery.
Materials and methods: PDAC patients who underwent radical resection between January 1999 and March 2015 were enrolled in this study. Tumor recurrence within 6 months after surgery was defined as ER. Immunohistochemical staining was performed with anti-CD44 antibodies. The association between clinicopathological parameters and CD44 expression was analyzed. Predictors for ER were also assessed with univariate and multivariate analyses.
Results: Overall, 155 patients were included in this study. Univariate analysis revealed CA19-9 levels (p=0.014), CD44 histoscores (H-scores; p=0.002), differentiation (p=0.010), nodal status (p=0.005), stage (p=0.003), vascular invasion (p=0.007), lymphatic invasion (p<0.001) and perineural invasion (p=0.042) as risk factors for ER. In multivariate analysis, high CA19-9 levels and CD44 H-scores and poor differentiation independently predicted ER.
Conclusion: High CA19-9 levels, CD44 H-scores and poor differentiation are independent predictors for ER in PDAC patients undergoing radical resection. Therefore, the determination of CD44 expression might help in identifying patients at a high risk of ER for more aggressive treatment after radical surgery.
Keywords: CD44; early recurrence; pancreatic cancer; surgery.
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Figures
Similar articles
-
Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7. Hepatobiliary Pancreat Dis Int. 2018. PMID: 30237091
-
Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348. World J Gastroenterol. 2015. PMID: 26309360 Free PMC article.
-
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.Clin Cancer Res. 2016 Dec 15;22(24):6069-6077. doi: 10.1158/1078-0432.CCR-16-0058. Epub 2016 Jun 9. Clin Cancer Res. 2016. PMID: 27283965
-
Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.Dis Markers. 2017;2017:3276806. doi: 10.1155/2017/3276806. Epub 2017 Jun 4. Dis Markers. 2017. PMID: 28659655 Free PMC article.
-
Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.World J Gastroenterol. 2017 Sep 21;23(35):6420-6428. doi: 10.3748/wjg.v23.i35.6420. World J Gastroenterol. 2017. PMID: 29085191 Free PMC article. Review.
Cited by
-
Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer.Cancers (Basel). 2021 May 11;13(10):2285. doi: 10.3390/cancers13102285. Cancers (Basel). 2021. PMID: 34064540 Free PMC article.
-
The Role of Cancer Stem Cells in Radiation Resistance.Front Oncol. 2020 Feb 20;10:164. doi: 10.3389/fonc.2020.00164. eCollection 2020. Front Oncol. 2020. PMID: 32154167 Free PMC article. Review.
-
CD95L Inhibition Impacts Gemcitabine-Mediated Effects and Non-Apoptotic Signaling of TNF-α and TRAIL in Pancreatic Tumor Cells.Cancers (Basel). 2021 Oct 30;13(21):5458. doi: 10.3390/cancers13215458. Cancers (Basel). 2021. PMID: 34771621 Free PMC article.
-
Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging.Theranostics. 2020 Feb 10;10(8):3413-3429. doi: 10.7150/thno.40688. eCollection 2020. Theranostics. 2020. PMID: 32206099 Free PMC article.
-
A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.Ann Transl Med. 2019 Sep;7(18):461. doi: 10.21037/atm.2019.08.35. Ann Transl Med. 2019. PMID: 31700897 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. - PubMed
-
- Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–579. - PubMed
-
- Hsu CP, Hsu JT, Liao CH, Kang SC, Lin BC, Hsu YP, Yeh CN, Yeh TS, Hwang TL. Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center. Asian J Surg. 2018;41(2):115–123. - PubMed
-
- Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology. 2013;144(6):1241–1248. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous